KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BeOne Medicines (ONC) Other Non Operating Income (2016 - 2025)

Historic Other Non Operating Income for BeOne Medicines (ONC) over the last 11 years, with Q3 2025 value amounting to -$19.0 million.

  • BeOne Medicines' Other Non Operating Income fell 26768.86% to -$19.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$20.6 million, marking a year-over-year decrease of 21541.61%. This contributed to the annual value of -$12.6 million for FY2024, which is 10410.47% down from last year.
  • As of Q3 2025, BeOne Medicines' Other Non Operating Income stood at -$19.0 million, which was down 26768.86% from $8.2 million recorded in Q2 2025.
  • BeOne Medicines' Other Non Operating Income's 5-year high stood at $336.7 million during Q3 2023, with a 5-year trough of -$800.2 million in Q4 2021.
  • Its 5-year average for Other Non Operating Income is -$37.3 million, with a median of $1.8 million in 2024.
  • As far as peak fluctuations go, BeOne Medicines' Other Non Operating Income skyrocketed by 45116.44% in 2021, and later crashed by 1485005.77% in 2022.
  • BeOne Medicines' Other Non Operating Income (Quarter) stood at -$800.2 million in 2021, then surged by 102.43% to $19.4 million in 2022, then decreased by 13.83% to $16.7 million in 2023, then tumbled by 182.0% to -$13.7 million in 2024, then crashed by 38.19% to -$19.0 million in 2025.
  • Its last three reported values are -$19.0 million in Q3 2025, $8.2 million for Q2 2025, and $4.0 million during Q1 2025.